Envestnet Asset Management Inc. Sells 5,911 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Envestnet Asset Management Inc. trimmed its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 6.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 84,372 shares of the company’s stock after selling 5,911 shares during the period. Envestnet Asset Management Inc. owned approximately 0.25% of TransMedics Group worth $5,261,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Atlas Capital Advisors Inc. bought a new stake in shares of TransMedics Group during the fourth quarter valued at approximately $31,000. Hager Investment Management Services LLC acquired a new stake in TransMedics Group during the fourth quarter worth $33,000. Sachetta LLC bought a new stake in TransMedics Group in the 4th quarter valued at $40,000. AlphaQuest LLC bought a new stake in TransMedics Group in the 4th quarter valued at $52,000. Finally, Arcadia Investment Management Corp MI acquired a new position in shares of TransMedics Group in the 4th quarter valued at $72,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $91.21 on Wednesday. The stock has a market capitalization of $3.09 billion, a P/E ratio of 97.03 and a beta of 2.14. TransMedics Group, Inc. has a 1 year low of $55.00 and a 1 year high of $177.37. The firm has a 50 day moving average of $73.24 and a 200-day moving average of $78.72. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.

Analysts Set New Price Targets

A number of analysts recently weighed in on TMDX shares. Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a research note on Wednesday, March 26th. Canaccord Genuity Group reiterated a “buy” rating and issued a $104.00 price objective on shares of TransMedics Group in a research note on Tuesday, March 11th. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $122.70.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.